Ignite Creation Date:
2025-12-24 @ 7:13 PM
Ignite Modification Date:
2026-02-21 @ 8:30 AM
Study NCT ID:
NCT02244203
Status:
COMPLETED
Last Update Posted:
2014-09-19
First Post:
2014-09-18
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 60732 in Healthy Male Volunteers
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}}, 'protocolSection': {'designModule': {'phases': ['PHASE1'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'DOUBLE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 56}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2009-02'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2014-09', 'lastUpdateSubmitDate': '2014-09-18', 'studyFirstSubmitDate': '2014-09-18', 'studyFirstSubmitQcDate': '2014-09-18', 'lastUpdatePostDateStruct': {'date': '2014-09-19', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2014-09-19', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2009-07', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Number of patients with clinically relevant changes in vital signs (blood pressure (BP), pulse rate (PR))', 'timeFrame': 'up to day 21 after start of treatment'}, {'measure': 'Number of patients with clinically relevant changes in 12-lead ECG', 'timeFrame': 'up to day 21 after start of treatment'}, {'measure': 'Number of patients with clinically relevant changes in laboratory parameters', 'timeFrame': 'up to day 21 after start of treatment'}, {'measure': 'Number of patients with clinically relevant changes in coagulation parameters', 'timeFrame': 'up to 72 hours after start of treatment', 'description': 'Parameters:\n\n* Activated partial thromboplastin time (aPTT)\n* Prothrombin time (PT)\n* HepTest®'}, {'measure': 'Number of patients with adverse events', 'timeFrame': 'up to 6 weeks'}, {'measure': 'Global assessment of tolerability by investigator on a 4-point scale', 'timeFrame': 'up to 21 days after start of treatment'}], 'secondaryOutcomes': [{'measure': 'Maximum measured concentration of the analyte in plasma (Cmax)', 'timeFrame': 'up to 264 hours after start of treatment'}, {'measure': 'Time from dosing to maximum measured concentration of the analyte in plasma (tmax)', 'timeFrame': 'up to 264 hours after start of treatment'}, {'measure': 'Area under the concentration-time curve of the analyte in plasma (AUC)', 'timeFrame': 'up to 264 hours after start of treatment'}, {'measure': 'Terminal rate constant of the analyte in plasma (λz)', 'timeFrame': 'up to 264 hours after start of treatment'}, {'measure': 'Terminal half-life of the analyte in plasma (t1/2)', 'timeFrame': 'up to 264 hours after start of treatment'}, {'measure': 'Mean residence time of the analyte in the body after oral administration (MRTpo)', 'timeFrame': 'up to 264 hours after start of treatment'}, {'measure': 'Apparent clearance of the analyte in plasma after extravascular administration (CL/F)', 'timeFrame': 'up to 264 hours after start of treatment'}, {'measure': 'Amount of analyte eliminated in urine from the time point t1 to time point t2 (Aet1-t2)', 'timeFrame': 'up to 264 hours after start of treatment'}, {'measure': 'Fraction of analyte eliminated in urine from time point t1 to time point t2 (fet1-t2)', 'timeFrame': 'up to 264 hours after start of treatment'}, {'measure': 'Renal clearance of the analyte from the time point t1 until the time point t2 (CLR,t1-t2)', 'timeFrame': 'Pre-dose, up to 264 hours after start of treatment'}, {'measure': 'Changes in activated partial thromboplastin time (aPTT)', 'timeFrame': 'Pre-dose, up to 72 hours after start of treatment'}, {'measure': 'Changes in prothrombin time (PT)', 'timeFrame': 'Pre-dose, up to 72 hours after start of treatment'}, {'measure': 'Prolongation of coagulation time by Heptest®', 'timeFrame': 'up to 72 hours after start of treatment'}, {'measure': 'Inhibition of FXa activity', 'timeFrame': 'Pre-dose up to 168 hours after start of treatment', 'description': "Russel's Viper Venom (RVV)"}, {'measure': 'Percentage inhibition of endogenous thrombin generation', 'timeFrame': 'up to 24 hours after start of treatment'}, {'measure': 'Percentage peak inhibition of thrombin generation', 'timeFrame': 'up to 24 hours after start of treatment'}, {'measure': 'Relative prolongation of time to maximum inhibition of thrombin generation', 'timeFrame': 'up to 24 hours after start of treatment'}, {'measure': 'Relative prolongation of lag time of thrombin generation', 'timeFrame': 'up to 24 hours after start of treatment'}, {'measure': 'Maximum effect (Emax)', 'timeFrame': 'up to 168 hours after start of treatment'}, {'measure': 'Time to maximum effect (tmax)', 'timeFrame': 'up to 168 hours after start of treatment'}, {'measure': 'Area under the effect curve (AUEC)', 'timeFrame': 'up to 168 hours after start of treatment'}]}, 'conditionsModule': {'conditions': ['Healthy']}, 'descriptionModule': {'briefSummary': 'Single Rising Dose (SRD) study: First evaluation of safety, tolerability, pharmacokinetics and pharmacodynamics of BI 60732'}, 'eligibilityModule': {'sex': 'MALE', 'stdAges': ['ADULT'], 'maximumAge': '45 Years', 'minimumAge': '18 Years', 'healthyVolunteers': True, 'eligibilityCriteria': "Inclusion Criteria:\n\n* Healthy males according to the following criteria: Based upon a complete medical history, including the physical examination, vital signs (BP, PR), 12-lead ECG, clinical laboratory tests\n* Age ≥ 18 and Age ≤ 45 years\n* BMI ≥ 18.5 and BMI ≤ 29.9 kg/m2 (Body Mass Index)\n* Signed and dated written informed consent prior to admission to the study in accordance with good clinical practice and the local legislation\n\nExclusion Criteria:\n\n* Any finding of the medical examination deviating from normal and of clinical relevance. Repeated measurement of a systolic blood pressure greater than 140 mm Hg or diastolic blood pressure greater than 90 mm Hg\n* Any evidence of a clinically relevant concomitant disease\n* Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders\n* Surgery of the gastrointestinal tract (except appendectomy)\n* Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders\n* History of relevant orthostatic hypotension, fainting spells or blackouts\n* Chronic or relevant acute infections\n* History of relevant allergy/hypersensitivity (including allergy to drug or its excipients)\n* Intake of drugs within one month or less than 10 half-lives of the respective drug prior to first study drug administration except if a relevant interaction can be ruled out\n* Participation in another trial with an investigational drug within 2 months prior to first study drug administration\n* Smoker (\\> 10 cigarettes or \\> 3 cigars or \\> 3 pipes/day)\n* Alcohol abuse (average consumption of more than 30 g / day)\n* Drug abuse\n* Blood donation (more than 100 mL within four weeks prior to the start of study)\n* Any laboratory value outside the reference range that is of clinical relevance\n* Inability to comply with dietary regimen of trial site\n* A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval \\>450 ms)\n* A history of additional risk factors for Torsade de pointes (e.g., heart failure, hypokalaemia, family history of Long QT Syndrome)\n* Anaemia at screening\n* Subjects who in the investigator's judgement are perceived as having an increased risk of bleeding, for example because of:\n\n * Hemorrhagic disorders or bleeding diathesis\n * Occult blood in faeces or haematuria\n * Trauma or surgery within the last month or as long as an excessive risk of bleeding persists after these events, or planned surgery during trial participation\n * History of arteriovenous malformation or aneurysm\n * History of gastroduodenal ulcer disease or gastrointestinal haemorrhage\n * History of intracranial, intraocular, spinal, retroperitoneal, or atraumatic intraarticular bleeding\n * Use of drugs that may interfere with haemostasis during trial conduct (e.g. acetylsalicylic acid or other non-steroidal anti-inflammatory drugs)\n * Thrombocytopenia (platelet count \\< 100/nL)"}, 'identificationModule': {'nctId': 'NCT02244203', 'briefTitle': 'Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 60732 in Healthy Male Volunteers', 'organization': {'class': 'INDUSTRY', 'fullName': 'Boehringer Ingelheim'}, 'officialTitle': 'Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of 0.25, 0.5, 1, 2, 4, 20, 50, 100, 150 and 200 mg BI 60732 Powder in Bottle (PIB) Administered to Healthy Male Volunteers in a Randomised, Double Blind, Placebo Controlled Phase I Trial', 'orgStudyIdInfo': {'id': '1267.1'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Single rising doses of BI 60732', 'interventionNames': ['Drug: BI 60732']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Placebo', 'interventionNames': ['Drug: Placebo']}], 'interventions': [{'name': 'BI 60732', 'type': 'DRUG', 'armGroupLabels': ['Single rising doses of BI 60732']}, {'name': 'Placebo', 'type': 'DRUG', 'armGroupLabels': ['Placebo']}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Boehringer Ingelheim', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}